Form 4: MAIA Biotechnology Head of Finance Acquires Stock Options

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Summary

• Jeffrey C Himmelreich, Head of Finance at MAIA Biotechnology, Inc., filed a Form 4 on May 15, 2025.
• The report details the grant of stock options on May 14, 2025, under the company's 2021 Equity Incentive Plan.
• Himmelreich acquired 40,000 stock options with an exercise price of $1.76.
• These options vest over a 4-year schedule, with 25% vesting on the first anniversary and the remainder vesting monthly over the subsequent 36 months.
• The options expire on May 14, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. It indicates alignment of interest but doesn't provide specific insights into company performance.

Positives

• The grant of stock options aligns the Head of Finance's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The stock option grant aligns the Head of Finance's interests with shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, Form 4, MAIA Biotechnology, insider trading, Jeffrey Himmelreich, equity incentive plan, beneficial ownership